NZ297797A - Benzenesulphonamide derivatives - Google Patents

Benzenesulphonamide derivatives

Info

Publication number
NZ297797A
NZ297797A NZ297797A NZ29779795A NZ297797A NZ 297797 A NZ297797 A NZ 297797A NZ 297797 A NZ297797 A NZ 297797A NZ 29779795 A NZ29779795 A NZ 29779795A NZ 297797 A NZ297797 A NZ 297797A
Authority
NZ
New Zealand
Prior art keywords
methoxy
phenoxy
ethoxy
pyridin
pyrimidin
Prior art date
Application number
NZ297797A
Other languages
English (en)
Inventor
Volker Breu
Jean-Marie Cassal
Georges Hirth
Marcel Muller
Henri Ramuz
Kaspar Burri
Martine Clozel
Bernd-Michael Loffler
Werner Neidhart
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NZ297797A publication Critical patent/NZ297797A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69Benzenesulfonamido-pyrimidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Bipolar Transistors (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Lubricants (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Surgical Instruments (AREA)
NZ297797A 1994-12-20 1995-12-08 Benzenesulphonamide derivatives NZ297797A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH383794 1994-12-20
CH241995 1995-08-24
PCT/EP1995/004843 WO1996019459A1 (en) 1994-12-20 1995-12-08 Novel sulfonamides

Publications (1)

Publication Number Publication Date
NZ297797A true NZ297797A (en) 1999-10-28

Family

ID=25690401

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ297797A NZ297797A (en) 1994-12-20 1995-12-08 Benzenesulphonamide derivatives

Country Status (25)

Country Link
US (1) US6004965A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0799209B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2989014B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100445085B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1098254C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE246681T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU701767B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9510104A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2208018C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY2495B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ287916B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69531457T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0799209T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2203649T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI120397B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU228619B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL116385A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA23744A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY131126A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO316645B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ297797A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT799209E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SA (1) SA95160421B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW313568B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1996019459A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
EP2002846B1 (en) 1996-12-06 2017-01-25 Amgen Inc. Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
ATE267808T1 (de) * 1997-08-19 2004-06-15 Hoffmann La Roche Verfahren zur herstellung von 2,5- disubstituierten pyridinen
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
ATE311382T1 (de) * 1998-08-10 2005-12-15 Verfahren zur herstellung von 2-carbamoyl- pyridinen
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
TWI284642B (en) 1999-01-18 2007-08-01 Hoffmann La Roche Novel heterocyclic sulfonamides
US6417360B1 (en) 1999-03-03 2002-07-09 Hoffmann-La Roche Inc. Heterocyclic sulfonamides
AU747596B2 (en) * 1999-05-22 2002-05-16 Actelion Pharmaceuticals Ltd Aqueous pharmaceutical composition
ZA200002318B (en) * 1999-05-22 2000-11-16 Actelion Pharmaceuticals Ltd Aqueous pharmaceutical composition.
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
CN100424079C (zh) * 1999-09-03 2008-10-08 埃科特莱茵药品有限公司 双磺胺
IL149529A0 (en) * 1999-12-22 2002-11-10 Actelion Pharmaceuticals Ltd Butyne diol derivatives
WO2001081338A1 (en) * 2000-04-25 2001-11-01 Actelion Pharmaceuticals Ltd Substituted sulfonylaminopyrimidines
US6387915B2 (en) 2000-05-31 2002-05-14 Pfizer Inc. Isoxazole-sulfonamide endothelin antagonists
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
MXPA03004780A (es) 2000-12-18 2004-05-21 Actelion Pharmaceuticals Ltd Nuevas sulfamidas.
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2002083650A1 (en) * 2001-04-11 2002-10-24 Actelion Pharmaceuticals Ltd Novel sulfonylamino-pyrimidines
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
CA2475703C (en) 2002-02-11 2016-12-20 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
ES2378670T3 (es) 2002-02-11 2012-04-16 Bayer Healthcare, Llc Aril ureas como inhibidores de cinasas
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
CN100379730C (zh) * 2002-12-02 2008-04-09 埃科特莱茵药品有限公司 嘧啶-磺酰胺及其作为内皮素受体拮抗剂的应用
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
JP2007511203A (ja) 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害活性を有するジアリール尿素
UA84156C2 (ru) 2003-07-23 2008-09-25 Байер Фармасьютикалс Корпорейшн Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
CA2558020A1 (en) 2004-03-17 2005-09-29 Novartis Ag Use of renin inhibitors in therapy
TW200628467A (en) 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
CA2657258A1 (en) 2006-07-20 2008-01-24 Novartis Ag Amino-piperidine derivatives as cetp inhibitors
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
BRPI0720218A2 (pt) 2006-12-08 2013-12-24 Lexicon Pharmaceuticals Inc Anticorpos monoclonais contra angptl3
US8871247B2 (en) 2007-02-19 2014-10-28 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
FR2921062A1 (fr) * 2007-09-17 2009-03-20 Commissariat Energie Atomique Composes utiles comme ligands et notamment comme chromophores organiques de complexation des lanthanides et leurs applications
MX2010004929A (es) 2007-11-05 2010-05-27 Novartis Ag Derivados de 4-bencil-amino-1-carboxi-acil-piperidina como inhibidores de proteina de transferencia de colesterol-ester (cetp) utiles para el tratamiento de enfermedades tales como hiperlipidemia o arteriosclerosis.
PT2229356E (pt) 2007-12-03 2012-01-20 Novartis Ag Derivados de 4-benzilamino-pirrolidina 1,2-dissubstituídos como inibidores de cetp úteis para o tratamento de doenças tais como hiperlipidemia ou arteriosclerose
ES2430088T3 (es) 2009-05-15 2013-11-18 Novartis Ag Derivados de benzoxazolona como inhibidores de aldosterona sintasa
PL2429995T3 (pl) 2009-05-15 2014-07-31 Novartis Ag Arylopirydyny jako inhibitory syntazy aldosteronu
SG176009A1 (en) 2009-05-28 2011-12-29 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
KR20120041702A (ko) 2009-05-28 2012-05-02 노파르티스 아게 네프릴리신 억제제로서의 치환된 아미노부티르산 유도체
JP5654608B2 (ja) 2009-11-17 2015-01-14 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのアリール−ピリジン誘導体
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
JP5575913B2 (ja) 2009-11-30 2014-08-20 ノバルティス アーゲー アルドステロン合成酵素阻害剤としてのイミダゾール誘導体
NZ602909A (en) 2010-04-15 2015-01-30 Marinepolymer Tech Inc Anti-bacterial applications of poly -n-acetylglucosamine nanofibers
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
EP2643019B1 (en) 2010-11-24 2019-01-02 Lexicon Pharmaceuticals, Inc. Antibodies to notum pectinacetylesterase
JP6144254B2 (ja) 2011-04-15 2017-06-07 マリン ポリマー テクノロジーズ,インコーポレーテッド ポリ−n−アセチルグルコサミンナノファイバを用いた疾患の治療
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
KR20150119109A (ko) 2013-02-14 2015-10-23 노파르티스 아게 Nep (중성 엔도펩티다제) 억제제로서의 치환된 비스페닐 부타노익 포스폰산 유도체
KR20160031552A (ko) 2013-07-25 2016-03-22 노파르티스 아게 합성 아펠린 폴리펩티드의 생체접합체
US9266925B2 (en) 2013-07-25 2016-02-23 Novartis Ag Cyclic polypeptides for the treatment of heart failure
CN107406490A (zh) 2015-01-23 2017-11-28 诺华股份有限公司 具有改善的半衰期的合成apelin脂肪酸缀合物
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
TWI835843B (zh) 2018-10-03 2024-03-21 瑞士商亨斯邁紡織染化(瑞士)有限公司 新的經吡啶及經嘧啶取代之三uv吸收劑
US20230373967A1 (en) 2020-11-05 2023-11-23 Idorsia Pharmaceuticals Ltd A stable crystalline hydrate of clazosentan disodium salt
KR20240121242A (ko) 2021-12-17 2024-08-08 넥세라 파마 씨오., 엘티디. 클라조센탄 디소듐 염, 이의 제조 및 이를 포함하는 약학 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW270116B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW287160B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1992-12-10 1996-10-01 Hoffmann La Roche
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
IL111959A (en) * 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
CZ287916B6 (cs) 2001-03-14
MY131126A (en) 2007-07-31
AU701767B2 (en) 1999-02-04
CA2208018A1 (en) 1996-06-27
BR9510104A (pt) 1997-11-25
CA2208018C (en) 2007-03-27
DE69531457D1 (en) 2003-09-11
EP0799209A1 (en) 1997-10-08
WO1996019459A1 (en) 1996-06-27
FI972628L (fi) 1997-06-18
DE69531457T2 (de) 2004-06-24
IL116385A0 (en) 1996-03-31
NO972538L (no) 1997-06-04
HU228619B1 (en) 2013-04-29
NO316645B1 (no) 2004-03-22
ATE246681T1 (de) 2003-08-15
FI120397B (fi) 2009-10-15
SA95160421B1 (ar) 2006-05-01
MX9704587A (es) 1998-07-31
CZ187497A3 (en) 1997-10-15
JPH10509182A (ja) 1998-09-08
ES2203649T3 (es) 2004-04-16
HUT77884A (hu) 1998-09-28
NO972538D0 (no) 1997-06-04
AU4304196A (en) 1996-07-10
KR100445085B1 (ko) 2004-10-14
DK0799209T3 (da) 2003-11-24
PT799209E (pt) 2003-12-31
CY2495B1 (en) 2005-09-02
FI972628A0 (fi) 1997-06-18
JP2989014B2 (ja) 1999-12-13
MA23744A1 (fr) 1996-07-01
CN1098254C (zh) 2003-01-08
CN1170407A (zh) 1998-01-14
IL116385A (en) 2000-07-16
HK1001973A1 (en) 1998-07-24
EP0799209B1 (en) 2003-08-06
TW313568B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1997-08-21
US6004965A (en) 1999-12-21

Similar Documents

Publication Publication Date Title
US6004965A (en) Sulfonamides
JP4245130B2 (ja) 新規なスルファミド類
TW394761B (en) Novel Sulfonylamino Pyrimidines
CA2359363C (en) 4-(heterocyclylsulfonamido)-5-methoxy-6-(2-methoxyphenoxy)-2-phenyl- or pyridylpyrimidines as endothelin receptor antagonists
NZ242396A (en) 6-hydroxyalkoxy-pyrimidin-4-yl benzenesulphonamide derivatives; pharmaceutical compositions and preparatory processes
US7091201B2 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
TW394763B (en) Sulfonamide compounds having inhibitory activity on endothelin receptors, their preparation process and pharmacentical compositions containing same
AU2002212171A1 (en) Arylalkane-sulfonamides having endothelin-antagonist activity
JP2723496B2 (ja) 新規なスルホニルアミノピリミジン類
JP3116347B2 (ja) 医薬組成物
RU2151767C1 (ru) Сульфонамиды и фармацевтическая композиция
NO327220B1 (no) Alkansulfonamider, fremgangsmate for fremstilling av slike, disse forbindelsene for anvendelse som medikamenter for behandling av lidelser samt anvendelse for fremstilling av medikamenter for behandling av lidelser
HK1001973B (en) Sulfonamides
MXPA97004587A (es) Sulfonamidas novedosas
EP1322624B1 (en) Arylalkane-sulfonamides having endothelin-antagonist activity

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired